SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

11 Nov 2022 Evaluate
A minor change in the total revenue was seen in the September 2022 quarter. The total revenue for the quarter stood at Rs. 24614.90 millions against Rs. 23639.90 millions during year ago period.Net Profit of the company move down -37.15% to Rs. 3506.90  millions from Rs. 5580.10 millions  in the same quarter last year.The Operating Profit of the company witnessed a decrease to 4793.20 millions from 6310.50 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 24614.90 23639.90 4.12 45198.40 46426.60 -2.65 88298.10 72196.80 22.30
Other Income 736.40 432.10 70.42 1289.50 824.20 56.45 1998.90 1900.10 5.20
PBIDT 4793.20 6310.50 -24.04 7179.40 12208.30 -41.19 20102.50 21389.40 -6.02
Interest 200.20 85.00 135.53 420.40 175.60 139.41 379.00 429.30 -11.72
PBDT 4593.00 6225.50 -26.22 6759.00 12032.70 -43.83 19723.50 20832.30 -5.32
Depreciation 577.40 538.20 7.28 1145.50 1055.40 8.54 2189.80 1989.30 10.08
PBT 4015.60 5687.30 -29.39 5613.50 10977.30 -48.86 17533.70 18843.00 -6.95
TAX 508.70 107.20 374.53 705.60 704.50 0.16 2121.20 1992.20 6.48
Deferred Tax -191.10 -882.40 -78.34 -269.30 -1201.30 -77.58 -917.00 -1326.10 -30.85
PAT 3506.90 5580.10 -37.15 4907.90 10272.80 -52.22 15412.50 16850.80 -8.54
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 19.47 26.69 -27.05 15.88 26.30 -39.59 22.77 29.63 -23.15

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×